Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Expenses (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Operating Expenses data on record, last reported at $14.5 million in Q3 2025.

  • For Q3 2025, Operating Expenses fell 4.21% year-over-year to $14.5 million; the TTM value through Sep 2025 reached $65.8 million, up 1.7%, while the annual FY2024 figure was $67.9 million, 18.19% up from the prior year.
  • Operating Expenses reached $14.5 million in Q3 2025 per NWBO's latest filing, down from $14.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $21.6 million in Q2 2022 and bottomed at $10.4 million in Q3 2021.
  • Average Operating Expenses over 5 years is $15.5 million, with a median of $15.2 million recorded in 2024.
  • The widest YoY moves for Operating Expenses: up 135.74% in 2021, down 78.38% in 2021.
  • A 5-year view of Operating Expenses shows it stood at $10.7 million in 2021, then surged by 75.86% to $18.8 million in 2022, then dropped by 16.98% to $15.6 million in 2023, then rose by 20.16% to $18.7 million in 2024, then decreased by 22.48% to $14.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $14.5 million in Q3 2025, $14.9 million in Q2 2025, and $17.7 million in Q1 2025.